Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6183)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2014 (publication date) through Dec 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i23/7207.htm |
| Number | Citing Articles |
| 1 |
Mi Na Kim, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang‐Hyub Han. Durability of the virological response after lamivudine discontinuation in lamivudine‐resistant patients with a complete virological response after lamivudine and adefovir combination therapy. Journal of Medical Virology 2017; 89(1): 85 doi: 10.1002/jmv.24616
|
| 2 |
Bryan R. Cobb, Alexandra Valsamakis, Randall T. Hayden, Donna M. Wolk, Karen C. Carroll, Yi-Wei Tang. Chronic Hepatitis B, C, and D. Microbiology Spectrum 2016; 4(4) doi: 10.1128/microbiolspec.DMIH2-0025-2015
|
| 3 |
Naruhiko Nagata, Tatehiro Kagawa, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Kazuya Anzai, Koichi Shiraishi, Tetsuya Mine. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0454-z
|
| 4 |
Li Gao, Yue Hu, Xiaofeng Shi, Xin Li, Dazhi Zhang, Hong Ren. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Annals of Hepatology 2020; 19(3): 329 doi: 10.1016/j.aohep.2019.10.006
|
| 5 |
Kyu Sik Jung, Jun Yong Park, Young Eun Chon, Hyon-Suk Kim, Wonseok Kang, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. Journal of Gastroenterology 2016; 51(8): 830 doi: 10.1007/s00535-015-1153-1
|
| 6 |
Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Ryo Shimizu, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masayuki Kitano. Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. Hepatitis Research and Treatment 2017; 2017: 1 doi: 10.1155/2017/2093847
|
| 7 |
Bryan R. Cobb, Alexandra Valsamakis. Diagnostic Microbiology of the Immunocompromised Host. 2016; : 69 doi: 10.1128/9781555819040.ch3
|